Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Diana Reeves

Chris Hugh Senanayake

Li Feng Zhang

Richard John Varsolona

Jinhua Jeff Song

Dhileepkumar Krishnamurthy

Rogelio Perez Frutos

Xiao-Jun Wang

Thomas Nicola

Zhi-Hui Lu

Jonathan Timothy Reeves

Yongda Zhang

Laurence John Nummy

Thomas Wirth

Daniel Robert Fandrick

Jutta Kroeber

Yibo Xu

Disclosed is a process for making diastereomeric compound of the formula (I): wherein m, n and Rto Rare as defined herein. The process of the invention provides the compound of formula (I) in high yield and substantially free of the corresponding diastereomers. The compounds of formula (I) prepared by the process of the invention are useful for making pharmaceutically active compounds such as 11-&#x3b2;-hydroxysteroid hydrogenase type 1 (11-&#x3b2;-HSD1) inhibitors.

Methods of making diastereomeric organic compounds

Disclosed is a multi-step process for preparing a compound of Formula I: wherein Rto Rare as defined herein. The compounds of formula I inhibit the binding of human intercellular adhesion molecules to the Leukointegrins. As a result, these compounds are useful in the treatment of inflammatory and immune cell-mediated diseases.

Synthesis of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides

Growing community of inventors

New Milford, CT, United States of America

Diana Reeves